by Richard Daverman, PhD
December 13, 2012 -- Veridex, a Johnson & Johnson company, received SFDA approval for CellSearch, an in vitro diagnostic device that tests for circulating tumor cells (CTC) in the bloodstream. The initial indication is women with metastatic breast cancer. In 2004, CellSearch was first approved in the US, also for metastatic breast cancer. Subsequently, it added indications for metastatic colon cancer and metastatic prostate cancer. More details....
Stock Symbol: (NYSE: JNJ)
